CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
Rhea-AI Summary
CytoMed Therapeutics (NASDAQ: GDTC) provided a 2026 update outlining clinical and corporate progress. The company is developing donor-derived gamma delta T cell therapies and advancing Natural Killer (NK) cell process development via subsidiary LongevityBank, with support from Enterprise Singapore. CytoMed says it has resources to fund operations for at least one year and may monetise real estate or pursue licensing/partnerships to reduce dilution. Key clinical items: a MoU with Universiti Malaya for a multi-site Phase I CTM-GDT trial in Malaysia with an IND targeted before June 2026, and an ongoing Phase I CAR T trial in Singapore with six patients treated. The company co-authored a Sept/Oct 2025 preclinical paper with MD Anderson. Chairman Peter Choo intends to increase his shareholding and the company seeks shareholder feedback on a proposal linking shareholding to patient access to therapies.
Positive
- Says it has resources to fund operations for at least one year
- MoU to start multi-site Phase I CTM-GDT trial in Malaysia; IND targeted before June 2026
- Ongoing Phase I CAR T trial in Singapore; 6 patients treated at two dose levels
- Enterprise Singapore support for NK cell development
- Co-authored Sept/Oct 2025 preclinical paper with MD Anderson
Negative
- Clinical-stage company with only early Phase I data; no approvals yet
- Funding runway stated as ~1 year, implying near-term financing or monetisation needs
- IND submission is pending with a target before June 2026, creating a near-term regulatory timeline risk
News Market Reaction
On the day this news was published, GDTC declined 1.61%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.7% during that session. Argus tracked a trough of -36.5% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $238K from the company's valuation, bringing the market cap to $15M at that time. Trading volume was elevated at 2.9x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GDTC showed a -6.06% move while key biotech peers were mixed: FBLG +12.07%, CRIS +7.65%, LIXT -5.82%, NRXS +5.53%, QTTB -0.55%. The mixed directions suggest a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Clinical trial plan | Positive | +4.5% | MoU for multi-site first-in-human Phase I γδ T cell trial in Malaysia. |
| Nov 06 | Subsidiary funding news | Positive | -3.3% | Non-dilutive investment into LongevityBank and China cell-therapy strategy update. |
| Oct 22 | Insider share purchase | Positive | +4.3% | Executive Chairman increased effective ownership to <b>21.95%</b> via open-market buys. |
| Oct 14 | Asset acquisition bid | Positive | +16.6% | Cash bid to acquire TC BioPharm assets to enhance γδ T cell platform. |
| Oct 02 | Research publication | Positive | +0.0% | Publication with MD Anderson showing potential of allogeneic γδ T cells in AML. |
Recent news has generally been positive and often met with positive price reactions, though there are instances where constructive updates coincided with short-term declines.
Over the last few months, CytoMed reported several advancing milestones. On Oct 2, 2025, it highlighted collaborative AML research with MD Anderson using allogeneic γδ T cells. A cash bid for TC BioPharm assets followed on Oct 14, aiming to deepen gamma delta T cell capabilities, and on Oct 22 the Chairman increased his effective stake to 21.95%. Subsequent updates in November and December 2025 detailed non-dilutive funding for LongevityBank and a planned first-in-human Phase I γδ T cell trial in Malaysia, supporting the current 2026 strategic and clinical update.
Market Pulse Summary
This announcement outlines CytoMed’s 2026 strategy, including low-cost Southeast Asia manufacturing, expansion of donor-derived γδ T cell and Natural Killer cell programs, and a planned Phase I trial in Malaysia targeting no-option cancer patients. Prior months featured an AML research publication, asset acquisitions, and non-dilutive funding, suggesting continued platform building. Investors may watch for regulatory milestones such as the planned Investigational New Drug submission and for updates on patient enrollment and safety data across both trials.
Key Terms
natural killer cells medical
gamma delta t cells medical
car t medical
investigational new drug regulatory
allogeneic medical
immunotherapies medical
hematological cancers medical
phase i medical
AI-generated analysis. Not financial advice.
SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will enhance access to rare and valuable cord blood as sources for cell-based allogeneic therapies. In addition to CytoMed’s gamma delta T cells, Natural Killer cells also express receptors that recognise stress ligands, allowing them to be cytotoxic tools to combat a wide variety of solid and hematological cancers. Notably, CytoMed’s efforts in development of Natural Killer cell therapy has recently received support from Enterprise Singapore, a Singapore government agency championing enterprise development.
For this new year 2026, the Company believes it has enough resources to continue funding its activities for at least a year given our low-cost infrastructure in Southeast Asia. Besides the usual capital market routes, CytoMed can look to licencing and asset monetisation from real estate properties which it owns and uses for operation. We are also continuously exploring proposals with sustainable benefits as we explore with long-term strategic partners including synergistic biotechs and hospitals which can strengthen the business and international aspects with less dilution. Notably CytoMed was ranked 4 out of 5 points in terms of investment potential in 2025 December’s Morning Star publication. As a matter of full disclosure, our Chairman Peter Choo intends to increase his shareholding in the Company and will make the relevant announcement as soon as possible.
As announced on December 8, 2025, CytoMed has entered into a Memorandum of Understanding with Universiti Malaya (“UM”) to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma Delta (γδ) T cells (CTM-GDT) (without genetically modifying the cells to express any receptor) for no-option cancer patients in Malaysia. We target to submit an Investigational New Drug application to the Malaysian authorities before June this year. This initiative complements CytoMed’s ongoing first-in-human Phase I chimeric antigen receptor T (CAR T) cell clinical trial at National University Hospital Singapore, which uses γδ T cells modified to express a CAR (CTM-N2D) targeting various cancer types, including advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinoma. To date, six patients had been treated at two dosage levels in Singapore.
Unmodified gamma delta T cells have been demonstrated in international clinical trials to have potential to kill cancer cells including brain cancers. CytoMed is co-author in a recent September/October 2025 publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach”. The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the great potential of CytoMed’s allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach.
Chairman Peter Choo commented, “Our allogeneic CAR T cells are on clinical trial and many no-option cancer patients with unmet needs or failed conventional cancer treatments have approached us. Healthcare cost in the West is prohibitive and is the main reason why international medical tourism is booming in Southeast Asia where costs are substantially lower than in the West. We believe we can manufacture clinical grade therapeutics in Southeast Asia at low cost.”
In line with above, the Company intends to seek feedback and opinion from shareholders on a novel scheme under which a shareholder can use his shareholding to get access to the Company’s donor-derived allogeneic unmodified gamma delta T cells subject to the doctor’s approval and home country regulations. Shareholders are encouraged to contact the Company for further information and share their ideas.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention: Evelyn Tan, Chief Corporate Officer
FAQ
What clinical trials is CytoMed (GDTC) running as of January 13, 2026?
When does CytoMed (GDTC) plan to submit an IND for the Malaysia CTM-GDT trial?
How long does CytoMed (GDTC) say it can fund operations without new capital?
What support did CytoMed (GDTC) receive for its NK cell development?
What recent research publication involves CytoMed (GDTC)?
What corporate actions did CytoMed (GDTC) announce for shareholder engagement?
